Pharmaceuticals

INOVIO and Advaccine Announce First Dosing of Subject in Phase 2 Clinical Trial for COVID-19 DNA Vaccine Candidate INO-4800 in China

PLYMOUTH MEETING, Pa. and SUZHOU, China, Dec. 10, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, and Advaccine Biopharmaceuticals Suzhou Co., Ltd. ("...

2020-12-10 21:00 5173

Bill and Melinda Gates call for collaboration, continued innovation to overcome challenges of delivering COVID-19 scientific breakthroughs to the world

Gates Foundation pledges additional $250 million to accelerate development and equitable distribution of COVID-19 tests, treatments, and vaccines to end the pandemic SEATTLE, Dec. 10, 2020 /PRNewswire/ -- The Bill & Melinda Gates Foundation today announced it will commit an additional$250 millio...

2020-12-10 13:01 1919

Stellar Results from Kintor's GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer: ORR Reached up to 40%

SHANGHAI, Dec. 10, 2020 /PRNewswire/ -- On December 9, 2020, Kintor Pharmaceutical Limited (HKEx: 9939) is pleased to announce that the Group has collected positive data in phase II clinical trials of combination therapy of ALK-1 (GT90001) antibody and PD-1 (Nivolumab or Opdivo) antibody for the ...

2020-12-10 12:14 2400

Ascentage Pharma Announces Updates on the Clinical Development of APG-2575, including an ORR of 70% in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

SUZHOU, China and ROCKVILLE, MD, Dec. 10, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced updates on the clinical devel...

2020-12-10 09:03 1883

CStone's Partner Blueprint Medicines Announces U.S. FDA Approval of GAVRETO (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer

SUZHOU, China, Dec. 10, 2020 /PRNewswire/ -- The partner of CStone Pharmaceuticals ("CStone", HKEX: 2616), Blueprint Medicines, announced on December 1st that the U.S. Food and Drug Administration (FDA) has approved GAVRETO™ (pralsetinib) for the treatment of patients with RET-altered thyroid can...

2020-12-10 08:30 3620

INOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Anal Dysplasia Caused by HPV-16/18

PLYMOUTH MEETING, Pa., Dec. 9, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and diseases associated with HPV, today announced positive Phase 2 efficacy ...

2020-12-09 21:00 3638

Zelgen Selects Industry's First Automated, End-to-End Drug Safety System

Rapidly growing biopharma selects ArisGlobal's LifeSphere® MultiVigilance 10, benefits from industry's first cognitive automation and AI-enabled safety system, a game-changer for patient safety MIAMI, Dec. 9, 2020 /PRNewswire/ -- ArisGlobal, the leading provider of life sciences software that au...

2020-12-09 05:07 1822

Henlius Adalimumab Biosimilar Approved by NMPA

SHANGHAI, Dec. 8, 2020 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the adalimumab biosimilar HLX03, developed and manufactured by the Company independently, has been approved by the National Medical Products Administration (NMPA) for the treatment of rheumatoid arthrit...

2020-12-08 21:00 2639

Novaliq Announces First Patient Randomized in the Phase 3 trial ESSENCE-2 of CyclASol® Topical Ophthalmic Solution for the Treatment of Dry Eye Disease

- ESSENCE-2 is the second registration trial to complete the clinical development of CyclASol® as agreed with U.S. Food and Drug Administration (FDA) - Designed to replicate efficacy demonstrated in previous phase 2/3 ESSENCE-1 trial - Topline data expected in 2nd half 2021 HEIDELBERG, Germany,...

2020-12-08 21:00 1225

Nuance Pharma Closes Series D Financing

SHANGHAI, Dec. 8, 2020 /PRNewswire/ -- Nuance Pharma, a biopharmaceutical company engaged in creating value throughChina's specialty pharmaceutical markets with an established focus on iron deficiency, pain management and respiratory, today announced that it has successfully closed its Series D ...

2020-12-08 17:34 2639

Nuance Pharma Closes Series D Financing

SHANGHAI, Dec. 8, 2020 /PRNewswire/ -- Nuance Pharma, a biopharmaceutical company engaged in creating value throughChina's specialty pharmaceutical markets with an established focus on iron deficiency, pain management and respiratory, today announced that it has successfully closed its Series D ...

2020-12-08 16:00 4099

Ascentage Pharma Announces Positive Data from Pivotal Phase II Studies of HQP1351 (Olverembatinib) in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) at 2020 American Society of Hematology (ASH) Annual Meeting

SUZHOU, China, and ROCKVILLE, MD, Dec. 8, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today reported positive data from two pivotal...

2020-12-08 08:16 2210

A­­­­­izon Lauded by Frost & Sullivan for Its AI-powered Platform that Enables Pharma Companies to Achieve Smart and Continuous Manufacturing

Aizon accelerates pharma manufacturing by bolstering the client's currently deployed technology with AI and ML capabilities to boost production performance SANTA CLARA, Calif., Dec. 7, 2020 /PRNewswire/ -- Based on its recent analysis of the North American artificial intelligence (AI) market for ...

2020-12-08 01:57 1486

PostEra enters a multi-year strategic partnership with Pfizer Inc. to advance machine learning for Drug Discovery

SAN FRANCISCO, Dec. 7, 2020 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning solutions for preclinical drug discovery, today announced a strategic partnership with Pfizer Inc. (NYSE: PFE) with the goal of accelerating small molecule drug discovery by developing a ...

2020-12-07 22:37 3690

INOVIO Doses First Subject in Phase 2 Segment of its INNOVATE Phase 2/3 Clinical Trial for INO-4800, its DNA Medicine to Prevent COVID-19

PLYMOUTH MEETING, Pa., Dec. 7, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced it has dosed its first subject in a Phase 2 clinical tr...

2020-12-07 21:00 3456

Antengene Announces Acceptance of IND Application in China for ATG-010 (selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study

SHANGHAI and HONG KONG, Dec. 7, 2020 /PRNewswire/ --  Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and on...

2020-12-07 08:00 3524

Polygiene and Eye-care innovator Body Doctor now increase the range of soothing eye compresses and face masks

STOCKHOLM, Dec. 4, 2020 /PRNewswire/ -- Body Doctor specializes in eye-care, eyelid hygiene products and have transformed the market for eye compresses and continue establishing a pedigree of bringing innovation to the sector with an antibacterial fabric thanks to the partnership with Polygiene®....

2020-12-04 16:23 2467

Ascentage Pharma Appoints Mr. Gang Zhu as Chief Commercial Officer to Lead Commercial Initiatives

SUZHOU, China and ROCKVILLE, Md., Dec. 4, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced the appointment of Mr. Gang Z...

2020-12-04 08:28 2394

Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study

HANGZHOU and SHAOXING, China, Dec. 4, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672) announces today that Phase IIa data demonstrated that ASC22 (Envafolimab) is safe and well tolerated in chronic hepatitis B (CHB) patients and Phase IIb clinical trial has been initiated. ASC22 (Envafolima...

2020-12-04 08:00 3545

INOVIO Expands Global Manufacturing Consortium For Its COVID-19 Vaccine Candidate INO-4800 With Addition of Kaneka Eurogentec S.A.

Partnership with leading global plasmid manufacturer advances INOVIO's INO-4800 Kaneka Eurogentec to support production of INO-4800 PLYMOUTH MEETING, Pa., Dec. 3, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to ...

2020-12-03 21:00 5586
1 ... 139140141142143144145 ... 183